The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Business development companies and real estate investment trusts dominate high-yield monthly payers, benefiting from high interest rates in 2025, though economic downturns pose challenges.

With Middle East tensions at a fever pitch, investors everywhere are flocking to safe-haven assets.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte …

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=152995&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=152997&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. ("Caleres" or the "Company") (NYSE:CAL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Hallador Energy Company ("Hallador" or the "Company") (NASDAQ:HNRG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of EchoStar Corporation ("EchoStar" or the "Company") (NASDAQ:SATS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc.("NWTN" or the "Company") (NASDAQ:NWTN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The West's energy watchdog said on Friday it was ready to release oil stocks should the market experience shortages following Israel's attack on Iran, drawing criticism from rival OPEC which said the statement would only create fear in the market.

Sam Altman is an influential visionary who is essentially the face of AI these days.

MoneyHero Limited (NASDAQ:MNY ) Q1 2025 Earnings Conference Call June 13, 2025 8:00 AM ET Company Participants Georgina Tan - Corporate Participant Ka Yip Leung - Interim CFO & Group Director of Finance Rohith Murthy - CEO & Director Conference Call Participants Vincent Chen - Unidentified Company William R. Gregozeski - Greenridge Global LLC Operator Good day, and thank you for standing by.

Year-ahead inflation expectations declined from 6.6% to 5.1%.

Dave's user base hits 12.4 million in Q1 2025, fueled by a new fee model and strategic marketing despite rising CAC.

Super Micro Computer Inc. (NASDAQ: SMCI) stock has its bullish supporters, some of whom feel it can withstand global trade issues and that it may be one of the best artificial intelligence (AI) stocks this year.

NEW YORK--(BUSINESS WIRE)---- $VSTS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) and reminds investors of the August 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline.